STAAR Surgical to Report Fourth Quarter and Fiscal Year Results on February 24, 2021

Rhea-AI Summary

STAAR Surgical Company (NASDAQ: STAA) has announced it will release its fourth-quarter and fiscal year financial results on February 24, 2021, post-market. The company will also hold a conference call at 4:30 p.m. Eastern to discuss these results and operational insights. STAAR specializes in developing and marketing implantable lenses and delivery systems for the eye, with over 1,000,000 Visian® ICLs implanted globally, illustrating its strong presence in the ophthalmic surgery market.

Positive

• STAAR has successfully implanted over 1,000,000 Visian® ICLs globally, indicating strong product demand.
• Upcoming Q4 and FY financial results announcement could signal potential growth and investor interest.

Negative

• None.

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the fourth quarter and fiscal year ended January 1, 2021 on Wednesday, February 24, 2021 after the market close.

STAAR will host a conference call and webcast on Wednesday, February 24 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 7649387), please dial 833-350-1429 for domestic participants and 647-689-6661 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Conference ID 7649387) will be available beginning approximately one hour after the call’s conclusion for seven days. This replay can be accessed by dialing 800-585-8367 for domestic callers and 416-621-4642 for international callers. An archived webcast will also be available at www.staar.com.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005227/en/

FAQ

When will STAAR Surgical announce its Q4 and fiscal year financial results?

STAAR Surgical will announce its financial results on February 24, 2021, after market close.

What time is STAAR Surgical's conference call for its financial results?

The conference call is scheduled for February 24, 2021, at 4:30 p.m. Eastern.

How can I access STAAR Surgical's conference call?

You can access the conference call by dialing 833-350-1429 for domestic or 647-689-6661 for international participants.

What is the significance of the Visian® ICL for STAAR Surgical?

The Visian® ICL is a key product for STAAR, with over 1,000,000 units implanted, highlighting its market penetration in ophthalmic surgery.